Bicycle Therapeutics (BCYC) Stock: Buy, Sell, or Hold?
BCYC - Bicycle Therapeutics plc American Depositary Shares
$3.86
0.03 (0.78%)
▲
5d:
-8.96%
30d:
-4.93%
90d:
-5.85%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Get Alerted When BCYC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BCYC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BCYC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCYC is currently trading at $3.86, which is considered oversold relative to its 30-day fair value range of $3.96 to $4.29.
Technical Outlook: Technically, BCYC is in a strong downtrend. The price is currently testing key support at $3.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BCYC scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.50 (+146.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCYC is in a strong downtrend. The price is currently testing key support at $3.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BCYC scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.50 (+146.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.96 -
$4.29
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (22/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 146.1% below Wall St target ($9.50)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.96 -
$4.29
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.81
Resistance Level
$4.44
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.74
Wall Street Target
$9.50
(+146.1%)
Revenue Growth (YoY)
-78.5%
Share & Embed Analysis
Last updated: September 13, 2026 3:51 AM ET
Data refreshes hourly during market hours. Next update: 4:51 AM
Data refreshes hourly during market hours. Next update: 4:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCYC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Kevin Lee
SELL
1716 shares
2026-04-06
Travis Alvin Thompson
SELL
102 shares
2026-04-06
Jennifer Scott Perry
SELL
370 shares
2026-04-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
